FOLH1 and prostate carcinoma: Intriguingly, prostate-specific membrane antigen (PSMA)-617 as a prostate cancer targeting ligand contains a naphthalene group, which allows it to insert into the cavity of CB [8] together with MV, thus endowing the supramolecular NP with targeting ability (Wright et al., 1995; Kratochwil et al., 2016; Feuerecker et al., 2021; Plichta et al., 2021).